EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Bone Health and Endocrine Therapy with Ovarian Function Suppression in Premenopausal Early Breast Cancer: A Real-Life Monocenter Experience with Denosumab

Angelachiara Rotondi, Valentina Frescura, Giorgia Arcuri iD, Giovanna Garufi, Letizia Pontolillo, Luca Mastrantoni, Elena Di Monte, Noemi Maliziola, Maria Antonia Fucile, Francesca Salvatori, Rita Mondello, Ilaria Poli und 7 weitere

Current Oncology · 26.07.2025 · 32 (8) · 421

DOI: 10.3390/curroncol32080421 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Current Oncology, online erschienen am 26.07.2025. Verfasst von Angelachiara Rotondi und 18 weiteren Autor:innen. Beteiligte Einrichtung: Comprehensive Cancer Center, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, 00168 Rome, Italy. Hauptthemen laut MEDLINE: Denosumab, Breast Neoplasms, Bone Density Conservation Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Adjuvant endocrine therapy for early breast cancer significantly reduces recurrence but increases bone fragility. Given limited data on denosumab (60 mg every 6 months) in premenopausal patients receiving endocrine therapy for early breast cancer, we conducted a retrospective real-world study at the Gemelli Hospital (September 2018–January 2025). A descriptive analysis was performed. The primary endpoint was to assess efficacy, evaluated by changes in bone mineral density via dual-energy X-ray absorptiometry and by monitoring bone turnover markers, particularly serum C-terminal telopeptide of type I collagen. Safety was evaluated based on adverse endocrine therapy events (osteoporotic fractures) and adverse denosumab events (osteonecrosis of the jaw). Sixty-nine patients were eligible for the study. Endocrine therapy included ovarian function suppression with exemestane (89.8%) or tamoxifen (10.1%). Baseline spinal osteoporosis decreased from 20.3% to 5.8%, osteopenia from 39.1% to 34.8%, with normal T-scores rising from 17.4% to 34.8%. Femoral improvements were similar. Serum C-terminal telopeptide of type I collagen levels (evaluated in 35.8%) showed stable reduction in 97%. Denosumab adherence was 89.9%. One osteonecrosis of the jaw case occurred (1.4%); no fractures were reported. Denosumab demonstrated efficacy in improving bone density and reducing bone turnover, with excellent adherence and favorable safety. Longer follow-up is needed to assess post-discontinuation effects.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DenosumabBreast NeoplasmsBone Density Conservation AgentsHumansFemaleAdultRetrospective StudiesPremenopauseMiddle AgedBone Density

Stichwörter der Autor:innen

adjuvant endocrine therapybone healthdenosumabearly breast cancerosteonecrosis of the jawosteoporosispremenopausal

Substanzen

DenosumabBone Density Conservation Agents

Autor:innen und Institutionen

  • Comprehensive Cancer Center, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, 00168 Rome, Italy.
  • Dipartimento di Medicina e Chirurgia Traslazionale, Università Cattolica del Sacro Cuore, 00168 Rome, Italy.
  • Precision Medicine in Breast Cancer Unit, Department of Woman and Child Health and Public Health, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, 00168 Rome, Italy.
  • Medical Oncology Unit, Ospedale Isola Tiberina-Gemelli Isola, 00186 Rome, Italy.

ORCID-Profile: Giorgia Arcuri, Alessandra Fabi, Armando Orlandi

Zitieren

APA

Rotondi, A., Frescura, V., Arcuri, G., Garufi, G., Pontolillo, L., Mastrantoni, L., Di Monte, E., Maliziola, N., Fucile, M. A., Salvatori, F., Mondello, R., Poli, I., Oliva, G. R., Mongelli, G., Palazzo, A., Fabi, A., Bria, E., Tortora, G., & Orlandi, A. (2025). Bone Health and Endocrine Therapy with Ovarian Function Suppression in Premenopausal Early Breast Cancer: A Real-Life Monocenter Experience with Denosumab. Current Oncology, 32(8), 421. https://doi.org/10.3390/curroncol32080421

Vancouver

Rotondi A, Frescura V, Arcuri G, Garufi G, Pontolillo L, Mastrantoni L, et al. Bone Health and Endocrine Therapy with Ovarian Function Suppression in Premenopausal Early Breast Cancer: A Real-Life Monocenter Experience with Denosumab. Current Oncology. 2025;32(8):421. doi:10.3390/curroncol32080421

BibTeX
@article{Rotondi2025,
  author = {Rotondi, Angelachiara and Frescura, Valentina and Arcuri, Giorgia and Garufi, Giovanna and Pontolillo, Letizia and Mastrantoni, Luca and Di Monte, Elena and Maliziola, Noemi and Fucile, Maria Antonia and Salvatori, Francesca and Mondello, Rita and Poli, Ilaria and Oliva, Gaia Rachele and Mongelli, Ginevra and Palazzo, Antonella and Fabi, Alessandra and Bria, Emilio and Tortora, Giampaolo and Orlandi, Armando},
  title = {Bone Health and Endocrine Therapy with Ovarian Function Suppression in Premenopausal Early Breast Cancer: A Real-Life Monocenter Experience with Denosumab},
  journal = {Current Oncology},
  year = {2025},
  volume = {32},
  number = {8},
  pages = {421},
  doi = {10.3390/curroncol32080421}
}
Kostenlos starten →